Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows

Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows
Lynparza (olaparib), a PARP inhibitor, significantly prevents ovarian cancer from progressing or returning in women who responded to their first-line chemotherapy treatment, results from a Phase 3 trial show. The randomized, double-blind, placebo-controlled study, called SOLO-1 (NCT01844986), assessed Lynparza as a maintenance therapy for patients with advanced ovarian cancer, who had a BRCA mutation in their tumor, and were at a high risk of progressing. Patients were still responding — partially or completely — to first-line platinum-based chemotherapy. Lynparza is the first PARP inhibitor showing benefits as a first-line maintenance treatment. Now that the trial has met its primary goal, AstraZeneca and Merck — which are jointly developing and commercializing Lynparza — are planning to submit the data to health authorities. “For the first time, we see a significant and clinically-impactful improvement in progression-free survival in the 1st-line maintenance setting for women with BRCA-mutated ovarian cancer treated with a PARP inhibitor," Sean Bohen, executive vice president of global medicines development and chief medical officer at AstraZeneca, said in a press release. "The SOLO-1 data reinforce the importance of knowing BRCA status at diagnosis, as this may enable women with BRCA-mutated ovarian cancer to receive Lynparza earlier. We would like to thank the investigators, hospitals and most of all, the patients who took part in this trial, without whom medical advancements would not be possible,” he said. Lynparza acts by preventing cells from repairing their DNA errors. Because cancer cells divide at a faster pace, they accumulate errors faster than healthy cells, leading to their death. Lynparza is particularly effective in
Subscribe or to access all post and page content.